Published in Cancer Epidemiol Biomarkers Prev on May 01, 2009
Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporos Int (2012) 4.09
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Primary prevention of colorectal cancer. Gastroenterology (2010) 3.20
Lower risk in parous women suggests that hormonal factors are important in bladder cancer etiology. Cancer Epidemiol Biomarkers Prev (2011) 1.04
Estrogen plus progestin and colorectal cancer incidence and mortality. J Clin Oncol (2012) 1.00
Postmenopausal hormone therapy and colorectal cancer risk by molecularly defined subtypes among older women. Gut (2011) 0.94
Menopausal hormone therapy use and risk of invasive colon cancer: the California Teachers Study. Am J Epidemiol (2010) 0.92
Hormone therapy, DNA methylation and colon cancer. Carcinogenesis (2010) 0.91
Racial differences in colorectal cancer incidence and mortality in the Women's Health Initiative. Cancer Epidemiol Biomarkers Prev (2011) 0.89
Common single-nucleotide polymorphisms in the estrogen receptor β promoter are associated with colorectal cancer survival in postmenopausal women. Cancer Res (2012) 0.86
Postmenopausal hormone therapy is associated with a reduced risk of colorectal cancer lacking CDKN1A expression. Cancer Res (2012) 0.84
Hormone replacement therapy, oral contraceptive use, and distal large bowel cancer: a population-based case-control study. Am J Gastroenterol (2010) 0.83
Menopausal hormone therapy and risks of colorectal adenomas and cancers in the French E3N prospective cohort: true associations or bias? Eur J Epidemiol (2012) 0.77
Atopic allergic conditions and colorectal cancer risk in the Multiethnic Cohort Study. Am J Epidemiol (2015) 0.77
Embedding clinical interventions into observational studies. Contemp Clin Trials (2015) 0.77
Estrogen receptor beta as target for colorectal cancer prevention. Cancer Lett (2015) 0.75
Eurocan Platform meeting: European recommendations for biomarker-based chemoprevention trials. Ecancermedicalscience (2014) 0.75
No association between germline variation in catechol-O-methyltransferase and colorectal cancer survival in postmenopausal women. Menopause (2014) 0.75
Menopausal Hormone Therapy, Age, and Chronic Diseases: Perspectives on Statistical Trends. Chem Res Toxicol (2016) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials (1998) 20.39
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol (2003) 7.49
Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med (2004) 5.65
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol (2008) 3.05
Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol (2008) 2.79
Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. Am J Med (1999) 2.42
Chemoprevention of colorectal cancer. N Engl J Med (2000) 1.98
Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy--long-term follow-up of a Swedish cohort. Int J Cancer (1996) 1.66
Estrogen plus progestin use, microsatellite instability, and the risk of colorectal cancer in women. Cancer Res (2007) 1.61
Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol (2006) 1.54
The women's health initiative: lessons learned. Annu Rev Public Health (2008) 1.50
Monitoring the randomized trials of the Women's Health Initiative: the experience of the Data and Safety Monitoring Board. Clin Trials (2007) 1.43
Conjugated equine estrogens and colorectal cancer incidence and survival: the Women's Health Initiative randomized clinical trial. Cancer Epidemiol Biomarkers Prev (2008) 1.42
Monitoring and reporting of the Women's Health Initiative randomized hormone therapy trials. Clin Trials (2007) 1.33
A meta-analysis of hormone replacement therapy and colon cancer in women. Cancer Epidemiol Biomarkers Prev (1998) 1.22
Estrogen affects post-menopausal women differently than estrogen plus progestin replacement therapy. Hum Reprod (2007) 1.04
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials (2005) 9.57
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med (2002) 7.77
National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med (2012) 6.46
Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA (2006) 5.75
Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med (2004) 5.65
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA (2008) 4.42
Use of recovery biomarkers to calibrate nutrient consumption self-reports in the Women's Health Initiative. Am J Epidemiol (2008) 4.28
Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. JAMA (2003) 4.07
Conjugated equine estrogens and coronary heart disease: the Women's Health Initiative. Arch Intern Med (2006) 3.91
Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol (2007) 3.88
Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. JAMA (2011) 3.85
American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol (2003) 3.71
Calcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst (2008) 3.60
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol (2012) 3.47
A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study. Control Clin Trials (2002) 3.41
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA (2006) 3.29
Obesity, body size, and risk of postmenopausal breast cancer: the Women's Health Initiative (United States). Cancer Causes Control (2002) 3.27
Mortality and cardiac and vascular outcomes in extremely obese women. JAMA (2006) 3.09
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol (2008) 3.05
Oophorectomy vs ovarian conservation with hysterectomy: cardiovascular disease, hip fracture, and cancer in the Women's Health Initiative Observational Study. Arch Intern Med (2011) 3.00
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97
Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: the Women's Health Initiative randomized trial. JAMA (2003) 2.90
Reproductive history and oral contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst (2011) 2.84